A Novel P53 Nanomedicine Reduces Immunosuppression and Augments Anti-PD-1 Therapy for Non-Small Cell Lung Cancer in Syngeneic Mouse Models

Lung cancer is among the most common and lethal cancers and warrants novel therapeutic approaches to improving patient outcomes. Although immune checkpoint inhibitors (ICIs) have demonstrated substantial clinical benefits, most patients remain unresponsive to currently approved ICIs or develop resis...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sang-Soo, Harford, Joe B., Moghe, Manish, Doherty, Caroline, Chang, Esther H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9654894/
https://www.ncbi.nlm.nih.gov/pubmed/36359830
http://dx.doi.org/10.3390/cells11213434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9654894/
https://www.ncbi.nlm.nih.gov/pubmed/36359830
http://dx.doi.org/10.3390/cells11213434

Ejemplares similares